Opioid Use Disorder (OUD)

This report summarises what Blossom’s database shows about psychedelic and dissociative compounds for opioid use disorder, and what it does not show. The short version: this is the addiction indication where honesty matters most, because opioids kill and effective treatment already exists. Against the backdrop of life-saving agonist medicines, ibogaine offers a real but uncontrolled anti-withdrawal signal wrapped in a serious risk of cardiac death, ketamine has old positive trials, and psilocybin has barely started. Nothing here is a proven opioid treatment, and nothing here should pull anyone away from medicines that work.

A note before the evidence

This page is a research summary, not medical advice, and nothing here is a treatment recommendation. None of the compounds discussed is an approved treatment for opioid use disorder. Crucially, methadone and buprenorphine are proven to save lives, and stopping or avoiding them in favour of an unproven psychedelic is dangerous. Opioid withdrawal and detoxification can be medically risky and should be done with professional support, and ibogaine specifically can cause fatal heart rhythm problems. If you or someone you know is struggling with opioids, evidence-based treatment is available now and is the right first step.

This page sits within Blossom’s Substance Use Disorders hub and is scoped to opioids specifically. A word on the numbers: Blossom tracks 40 papers and 25 trials tagged to this topic, and those counts appear on the page. The tag is leaky, pulling in tobacco, cluster-headache, general-addiction and population-survey work, so the genuinely opioid-specific clinical core is small, around a dozen studies, almost all ibogaine or ketamine. Read the counts as breadth of coverage, not as the depth of the opioid evidence.

Start with what works: the medication backdrop

It would be irresponsible to discuss psychedelics for opioids without first being clear about the standard of care, because the standard of care is genuinely good. Methadone and buprenorphine are opioid agonist medicines with one of the strongest evidence bases in addiction medicine: a meta-analysis of cohort studies found all-cause mortality roughly three times higher off methadone treatment than on it, and overdose mortality several times higher, with similar protection from buprenorphine[1]BMJ, opioid substitution mortality meta-analysis (2017). In plain terms, staying in treatment more than halves the risk of dying. That is the bar. Every compound below should be read as a candidate addition to this care, not a replacement for it, and the common claim that these medicines have "limited efficacy" is both wrong and dangerous.

Ibogaine: a real signal and a real danger

Ibogaine is the compound most specifically tied to opioids, and the anti-withdrawal signal is striking. An observational study of 30 opioid-dependent people found withdrawal scores roughly halved within days, with half opioid-free at one month[2]Am. J. Drug & Alcohol Abuse, ibogaine detox (2018); a large open-label case series of 191 people reported reduced withdrawal and craving[3]Frontiers in Pharmacology, ibogaine case series (2018); and a New Zealand follow-up found drug-use and depression reductions sustained to twelve months[4]Am. J. Drug & Alcohol Abuse, ibogaine 12-month (2018). People often describe a single session interrupting a dependence that nothing else had touched. Taken at face value, that is remarkable.

It must not be taken purely at face value, for two reasons. First, all of this evidence is uncontrolled, observational, open-label, retrospective, with no rigorous efficacy trial and no human meta-analysis. Second, and more seriously, ibogaine is cardiotoxic. It blocks a cardiac potassium channel, prolongs the QT interval and can cause torsades de pointes, a fatal arrhythmia: a formal safety study found clinically significant QT prolongation in a large proportion of patients[5]Addiction, ibogaine safety study (2022), it is bluntly described as neurotoxic and cardiotoxic and linked to deaths by cardiac arrest[6]ACS Chem. Neuroscience, DARK Classics: Ibogaine (2018), and reviews have catalogued fatalities[7]J. Substance Abuse Treatment, ibogaine review (2022). Dozens of ibogaine-associated deaths have been reported, overwhelmingly in unregulated clinics and ceremonies without cardiac screening or monitoring. The same loosely controlled settings produce both the encouraging stories and the bodies.

The most constructive response to that danger is to engineer around it. One approach co-administers intravenous magnesium to buffer the heart, the method used in a 2024 study of magnesium-ibogaine in veterans with traumatic brain injury (not opioid use disorder), which reported no serious cardiac events[8]Nature Medicine, magnesium-ibogaine in veterans (2024); another develops ibogaine analogues designed to keep the anti-addiction effect while shedding the cardiac toxicity. Both are promising and neither is proven for opioids. Until a controlled trial shows ibogaine can reduce opioid use safely, the honest position is that its power and its lethality are, for now, inseparable.

Ketamine: the oldest real trials

Ketamine has the distinction of the oldest genuine randomised trials in psychedelic addiction medicine, both in heroin dependence and both from a single Russian group. The first (n=70) compared a higher, psychedelic-dose ketamine-assisted psychotherapy against a low dose and found greater abstinence and longer craving reduction over two years[9]J. Substance Abuse Treatment, Krupitsky ketamine (2002); the second (n=59) found that three ketamine sessions produced one-year abstinence of 50%, against about 22% for a single session[10]J. Psychoactive Drugs, Krupitsky ketamine (2007).

That is real randomised evidence, and it should be given its due. But it should also be kept in proportion: the trials are small, single-site, two decades old, and have barely been replicated in opioid use disorder, and a review of ketamine across substance use disorders found the opioid work encouraging but largely not placebo-controlled[11]Frontiers in Psychiatry, ketamine SUD review (2018). Modern OUD ketamine trials are only now recruiting. Ketamine is a credible, under-tested idea whose best evidence is old, not an established opioid treatment.

Psilocybin and MDMA: barely begun

For psilocybin, the opioid story is almost all future. The only opioid-specific published study is a two-person feasibility report showing psilocybin can be given safely to people stabilised on buprenorphine[12]Psychedelic Medicine, psilocybin + buprenorphine (2023), with no efficacy claim. The wider rationale leans on population associations, such as a national survey linking lifetime psilocybin use to lower odds of opioid use disorder[13]Scientific Reports, psilocybin-OUD association (2022), which is suggestive but cannot establish cause. A cluster of Phase 2 psilocybin trials is now recruiting, so this is a section to revisit, not to rely on. MDMA, similarly, has no opioid-specific efficacy data and is relevant only for the common comorbidity of opioid use disorder with post-traumatic stress, where it is being tested to treat the trauma rather than the addiction.

How might these work?

The mechanisms are partly understood and partly hypothesis. Ibogaine is genuinely unusual pharmacologically: it and its long-lived metabolite noribogaine act at opioid, serotonin, nicotinic and NMDA receptors and the monoamine transporters all at once[14]Psychopharmacology, ibogaine receptor profile (1995), and this broad, multi-target action is thought to underlie both its anti-withdrawal effect and, unfortunately, its cardiac toxicity. Ketamine works mainly by blocking the NMDA receptor and is thought to promote a window of neuroplasticity. For the classic psychedelics, the proposed mechanism is the familiar 5-HT2A-driven plasticity plus a meaningful psychological experience, but for opioids that remains conjecture, since the trials that would test it have not reported.

Reading this honestly

So where does opioid use disorder sit? It is the clearest case in this field for leading with caution rather than promise. There is a real, repeatedly observed signal that ibogaine can lift opioid withdrawal, and there are genuine, if old, randomised data for ketamine, both of which deserve serious, careful study. But opioids already have treatments that save lives, ibogaine can kill through its effect on the heart, and the most exciting newcomer, psilocybin, has essentially no results yet. The honest conclusion is not cynicism, these signals are worth chasing, but a firm ordering of priorities: keep people on the proven medicines, study the psychedelics rigorously and safely as possible additions, and treat the gap between ibogaine’s underground promise and its underground death toll as the central problem to solve. For a condition this lethal, getting that order right is not pedantry; it is the whole point.